Exicure, Inc. (XCUR): Price and Financial Metrics
GET POWR RATINGS... FREE!
XCUR POWR Grades
- XCUR scores best on the Sentiment dimension, with a Sentiment rank ahead of 58.6% of US stocks.
- The strongest trend for XCUR is in Sentiment, which has been heading up over the past 35 days.
- XCUR ranks lowest in Momentum; there it ranks in the 18th percentile.
XCUR Stock Summary
- Exicure Inc's market capitalization of $26,154,883 is ahead of only 4.75% of US-listed equities.
- As for revenue growth, note that XCUR's revenue has grown -102.91% over the past 12 months; that beats the revenue growth of only 0.54% of US companies in our set.
- In terms of volatility of its share price, XCUR is more volatile than 99.2% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Exicure Inc, a group of peers worth examining would be CBIO, CDTX, IVA, AFMD, and ZYME.
- XCUR's SEC filings can be seen here. And to visit Exicure Inc's official web site, go to www.exicuretx.com.
XCUR Valuation Summary
- In comparison to the median Healthcare stock, XCUR's price/sales ratio is 196.92% higher, now standing at 33.7.
- XCUR's price/sales ratio has moved up 21.1 over the prior 40 months.
- Over the past 40 months, XCUR's EV/EBIT ratio has gone up 7.2.
Below are key valuation metrics over time for XCUR.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| XCUR | 2021-08-31 | 33.7 | 3.4 | -2.6 | -2.2 |
| XCUR | 2021-08-30 | 32.3 | 3.2 | -2.4 | -2.1 |
| XCUR | 2021-08-27 | 33.0 | 3.3 | -2.5 | -2.2 |
| XCUR | 2021-08-26 | 32.3 | 3.2 | -2.4 | -2.1 |
| XCUR | 2021-08-25 | 32.0 | 3.2 | -2.4 | -2.1 |
| XCUR | 2021-08-24 | 30.6 | 3.1 | -2.3 | -2.0 |
XCUR's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- XCUR has a Quality Grade of C, ranking ahead of 38.19% of graded US stocks.
- XCUR's asset turnover comes in at 0.039 -- ranking 338th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows XCUR's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.039 | 1 | -0.674 |
| 2021-03-31 | 0.085 | 1 | -0.500 |
| 2020-12-31 | 0.161 | 1 | -0.327 |
| 2020-09-30 | 0.157 | 1 | -0.336 |
| 2020-06-30 | 0.152 | 1 | -0.444 |
| 2020-03-31 | 0.133 | 1 | -0.757 |
XCUR Price Target
For more insight on analysts targets of XCUR, see our XCUR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $10.00 | Average Broker Recommendation | 1.38 (Strong Buy) |
XCUR Stock Price Chart Interactive Chart >
XCUR Price/Volume Stats
| Current price | $0.13 | 52-week high | $1.98 |
| Prev. close | $0.12 | 52-week low | $0.10 |
| Day low | $0.12 | Volume | 9,750,700 |
| Day high | $0.13 | Avg. volume | 12,958,305 |
| 50-day MA | $0.17 | Dividend yield | N/A |
| 200-day MA | $0.56 | Market Cap | 15.42M |
Exicure, Inc. (XCUR) Company Bio
Exicure, Inc. operates as a clinical stage bio-technology company. The Company develops a new class of immunomodulatory and gene regulating drugs against validated targets, as well as addresses diseases such as oncology, immunology, and dermatology. Exicure serves customers in the United States.
Latest XCUR News From Around the Web
Below are the latest news stories about Exicure Inc that investors may wish to consider to help them evaluate XCUR as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayRise and shine, trader! |
Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsightLas Vegas, USA, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight Toll-Like Receptor Agonist Pipeline constitutes 45+ key companies continuously working towards developing 45+ Toll-Like Receptor Agonist treatment therapies, analyzes DelveInsight DelveInsight''s Toll-Like Receptor Agonist Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Toll-Like Receptor Agonist pipeline domain. Some of the essential takeaways from the Toll-Like Receptor Agonist Pipeline report: DelveInsight''s Toll-Like Receptor (TLR) Agonist... |
Final Deadline Alert: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact The FirmFinal Deadline Alert: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact The Firm |
Deadline Tomorrow Reminder: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact The FirmDeadline Tomorrow Reminder: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact The Firm |
Deadline Friday Notice: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact The FirmDeadline Friday Notice: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact The Firm |
XCUR Price Returns
| 1-mo | -7.14% |
| 3-mo | -35.10% |
| 6-mo | -72.28% |
| 1-year | -92.22% |
| 3-year | -95.49% |
| 5-year | N/A |
| YTD | -35.68% |
| 2021 | -88.58% |
| 2020 | -38.11% |
| 2019 | -19.21% |
| 2018 | N/A |
| 2017 | N/A |
Continue Researching XCUR
Want to do more research on Exicure Inc's stock and its price? Try the links below:Exicure Inc (XCUR) Stock Price | Nasdaq
Exicure Inc (XCUR) Stock Quote, History and News - Yahoo Finance
Exicure Inc (XCUR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...